First Time Loading...
W

Wanbangde Pharmaceutical Holding Group Co Ltd
SZSE:002082

Watchlist Manager
Wanbangde Pharmaceutical Holding Group Co Ltd
SZSE:002082
Watchlist
Price: 5.11 CNY -0.58% Market Closed
Updated: May 19, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

4.3B
-2%
Assets
Growth Rates:
1 Year
+2%
3 Years
-24%
5 Years
+51%
7 Years
+159%
10 Years
+177%
1.6B
-8%
Liabilities
Growth Rates:
1 Year
+7%
3 Years
-46%
5 Years
+21%
7 Years
+495%
10 Years
+342%
2.7B
+2%
Equity
Growth Rates:
1 Year
-1%
3 Years
+1%
5 Years
+78%
7 Years
+92%
10 Years
+126%

Balance Sheet Decomposition
Wanbangde Pharmaceutical Holding Group Co Ltd

4.3B
Assets
1.6B
Liabilities
4.3B
Assets
1.6B
Liabilities
Current Assets 1.9B
Cash & Short-Term Investments 218.2m
Receivables 1.2B
Other Current Assets 471.2m
Non-Current Assets 2.4B
Long-Term Investments 10.5m
PP&E 1.5B
Intangibles 590.1m
Other Non-Current Assets 277.5m
Current Liabilities 1.3B
Accounts Payable 278.4m
Accrued Liabilities 74.6m
Short-Term Debt 862.8m
Other Current Liabilities 110.9m
Non-Current Liabilities 312.1m
Long-Term Debt 93.5m
Other Non-Current Liabilities 218.6m

Balance Sheet
Wanbangde Pharmaceutical Holding Group Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
260
276
557
281
399
782
566
907
468
218
Cash
11
13
16
8
1
79
0
907
468
218
Cash Equivalents
250
263
541
273
399
703
566
0
0
0
Total Receivables
345
494
423
502
518
1 240
1 395
1 206
1 332
1 234
Accounts Receivables
83
114
57
189
260
942
1 082
941
1 053
962
Other Receivables
261
380
366
313
258
298
312
265
279
272
Inventory
356
313
182
429
523
783
851
261
283
256
Other Current Assets
61
16
27
26
194
227
271
95
118
215
Total Current Assets
1 021
1 099
1 189
1 237
1 634
3 031
3 082
2 469
2 201
1 923
PP&E Net
462
451
404
510
583
1 248
1 783
1 175
1 274
1 495
PP&E Gross
462
451
404
510
583
1 248
1 783
1 175
1 274
1 495
Accumulated Depreciation
428
463
512
620
685
850
915
439
530
599
Intangible Assets
60
59
58
140
286
502
504
418
456
465
Goodwill
0
0
0
188
299
291
218
195
128
125
Note Receivable
0
0
0
0
0
0
6
4
7
13
Long-Term Investments
5
5
5
6
6
6
15
13
12
11
Other Long-Term Assets
2
4
3
20
39
32
55
98
140
265
Other Assets
0
0
0
188
299
291
218
195
128
125
Total Assets
1 551
N/A
1 617
+4%
1 658
+3%
2 100
+27%
2 845
+35%
5 110
+80%
5 662
+11%
4 371
-23%
4 218
-4%
4 296
+2%
Liabilities
Accounts Payable
66
65
68
128
149
307
340
241
219
278
Accrued Liabilities
14
17
25
38
45
78
130
99
68
75
Short-Term Debt
128
132
112
106
766
991
1 132
658
726
863
Current Portion of Long-Term Debt
0
0
0
0
0
9
12
32
38
57
Other Current Liabilities
33
42
46
194
135
202
251
254
87
54
Total Current Liabilities
241
257
251
467
1 095
1 587
1 865
1 283
1 137
1 327
Long-Term Debt
0
0
0
0
0
567
747
238
149
93
Deferred Income Tax
0
0
0
23
21
30
31
34
39
41
Minority Interest
11
10
14
182
231
293
237
146
131
101
Other Liabilities
14
14
11
8
6
96
161
72
75
76
Total Liabilities
265
N/A
280
+6%
276
-2%
679
+146%
1 353
+99%
2 572
+90%
3 041
+18%
1 773
-42%
1 531
-14%
1 639
+7%
Equity
Common Stock
238
238
238
238
238
238
618
618
618
617
Retained Earnings
806
857
903
942
1 026
1 164
1 708
1 751
1 844
1 820
Additional Paid In Capital
242
242
242
242
242
1 141
320
306
306
312
Treasury Stock
0
0
0
0
0
0
0
51
60
60
Other Equity
0
0
0
0
13
6
24
26
21
31
Total Equity
1 286
N/A
1 337
+4%
1 383
+3%
1 422
+3%
1 493
+5%
2 538
+70%
2 622
+3%
2 598
-1%
2 687
+3%
2 658
-1%
Total Liabilities & Equity
1 551
N/A
1 617
+4%
1 658
+3%
2 100
+27%
2 845
+35%
5 110
+80%
5 662
+11%
4 371
-23%
4 218
-4%
4 296
+2%
Shares Outstanding
Common Shares Outstanding
238
238
238
238
238
238
618
614
613
612

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.